Why the study?
Does encainide and its active metabolites suppress ventricular arrhythmias and prolong electrocardiographic intervals in patients with resistant ventricular ectopic depolarizations?
Population
8 patients with stable, high frequency ventricular ectopic depolarizations resistant to conventional…
Comparison
Encainide administered as an acute intravenous… vs Baseline.
Design
Cohort, Interval measurements and arrhythmia frequency analysis were performed…
Follow-up
Acute (hours) and sustained oral therapy (at least 4 days)
Authors
Loading...
Encainide effects vary by metabolizer phenotype; supports pharmacogenetic research but should not yet change practice.
Does encainide and its active metabolites suppress ventricular arrhythmias and prolong electrocardiographic intervals in patients with resistant ventricular ectopic depolarizations?
Encainide's antiarrhythmic and electrocardiographic effects are primarily mediated by its active metabolite ODE in extensive metabolizers, while the parent drug is active at high concentrations in poor metabolizers.
Carey et al. (1984) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: